Anti-diabetes mellitus potential of butterfly pea flower (Clitoria ternatea L.) extract based on antioxidant and inhibition of a-amylase and a-glucosidase activities

Le résumé fourni par la source

Type-2 diabetes (T2DM) is a condition that occurs when insulin production is insufficient. The prolonged process of imperfect insulin secretion results in hyperglycemia. Hyperglycemia-induced oxidative stress exacerbates diabetes complications. a-amylase and a-glucosidase also need to be inhibited to reduce blood glucose levels. So far, the available treatments for diabetes still cause side effects. On the other hand, the flowers of Clitoria ternatea L. are reported to have bioactivities such as antidiabetic, antimicrobial, antiproliferative, and anticancer. The purpose of this research is to evaluate the ability of C. ternatea flower extract (CFE) as an antidiabetic through its capacity as an antioxidant agent, as well as its ability to inhibit a-amylase and a-glucosidase. Antioxidant activity was measured using the 2,2-Diphenyl-1-picrylhydrazyl (DPPH), 2,22-Azinobis-(3-ethylbenzothiazoline-6-sulfonic acid) (ABTS), and hydrogen peroxide (H2O2)-reducing activity assays. Meanwhile, antidiabetic potential based on the ability to inhibit enzymes was carried out using a-amylase and a-glucosidase inhibitory assays. CFE demonstrated the antioxidant scavenging capacity of ABTS, DPPH, and H2O2 in a dose-dependent manner, with IC50 obtained of 65.70±0.01 µg/ml, 55.29±0.32 µg/ml, and 287.95±10.83 µg/ml, respectively. In addition, CFE also demonstrated its capacity to inhibit the enzymes a-amylase and a-glucosidase with IC50 of 83.49 µg/ml and 39.77 µg/ml. CFE demonstrated the capacity of an antioxidant agent and was able to hinder the activity of a-amylase and a-glucosidase. This shows that CFE has potential as a medication for type 2 diabetes mellitus.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.